flutamide has been researched along with Low Bone Density in 7 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
| Excerpt | Relevance | Reference |
|---|---|---|
| "One hundred and seventeen elderly male subjects [60 men without symptoms of prostate hyperplasia, 42 men with untreated benign prostatic hyperplasia (BPH), and 15 men with prostate cancer (PCa)] treated with finasteride or flutamide were included." | 3.78 | Prostate cancer in elderly Croatian men: 5-HT genetic polymorphisms and the influence of androgen deprivation therapy on osteopenia--a pilot study. ( Cvijetić, S; Dodig, S; Jurasović, J; Milković-Kraus, S; Mück-Šeler, D; Mustapić, M; Pašalić, D; Pauković, P; Pavlović, M; Pivac, N; Pizent, A, 2012) |
| " The present study was undertaken to determine whether androgen blockade with flutamide (15 mg/kg body weight orally daily) would influence bone turnover or bone composition (1) in female rats with intact ovaries and (2) in rats made estrogen-deficient with the luteinizing hormone releasing hormone (LHRH) agonist, buserelin (25 micrograms/kg body weight per day SC)." | 3.68 | Flutamide-mediated androgen blockade evokes osteopenia in the female rat. ( Gold, E; Goulding, A, 1993) |
| "Men with prostate cancer who lacked radiographically detectable metastases were treated in a prospective trial of IAD." | 2.77 | Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer. ( Chen, S; Gambol, TE; Gulati, R; Hall, SP; Higano, CS; Jiang, PY; Kuo, KF; Pitzel, P; Yu, EY, 2012) |
| "Seventy-one patients with localized prostate cancer, who received ADT, were prospectively studied based on their bone mineral density (BMD) and blood and urine samples at the baseline and after ADT for 6 months." | 2.75 | Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis. ( Hara, N; Hoshii, T; Isahaya, E; Nishiyama, T; Takahashi, K; Takizawa, I, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Malamas, MS | 1 |
| Manas, ES | 1 |
| McDevitt, RE | 1 |
| Gunawan, I | 1 |
| Xu, ZB | 1 |
| Collini, MD | 1 |
| Miller, CP | 1 |
| Dinh, T | 1 |
| Henderson, RA | 1 |
| Keith, JC | 1 |
| Harris, HA | 1 |
| Chernichenko, OA | 1 |
| Sakalo, VS | 1 |
| Yakovlev, PG | 1 |
| Sakalo, AV | 1 |
| Zhylchuk, YV | 1 |
| Zsolt, A | 1 |
| Isahaya, E | 1 |
| Hara, N | 1 |
| Nishiyama, T | 1 |
| Hoshii, T | 1 |
| Takizawa, I | 1 |
| Takahashi, K | 1 |
| Pašalić, D | 1 |
| Pauković, P | 1 |
| Cvijetić, S | 1 |
| Pizent, A | 1 |
| Jurasović, J | 1 |
| Milković-Kraus, S | 1 |
| Dodig, S | 1 |
| Mück-Šeler, D | 1 |
| Mustapić, M | 1 |
| Pivac, N | 1 |
| Pavlović, M | 1 |
| Yu, EY | 1 |
| Kuo, KF | 1 |
| Gulati, R | 1 |
| Chen, S | 1 |
| Gambol, TE | 1 |
| Hall, SP | 1 |
| Jiang, PY | 1 |
| Pitzel, P | 1 |
| Higano, CS | 1 |
| Goulding, A | 1 |
| Gold, E | 1 |
| Berruti, A | 1 |
| Dogliotti, L | 1 |
| Terrone, C | 1 |
| Cerutti, S | 1 |
| Isaia, G | 1 |
| Tarabuzzi, R | 1 |
| Reimondo, G | 1 |
| Mari, M | 1 |
| Ardissone, P | 1 |
| De Luca, S | 1 |
| Fasolis, G | 1 |
| Fontana, D | 1 |
| Rossetti, SR | 1 |
| Angeli, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Phase IV Study to Evaluate Variation in Bone Mineral Density, Lean and Fat Body Mass Index Measured by Dual-energy X-ray Absorptiometry in Patients With Prostate Cancer Without Bone Metastasis Treated With Degarelix[NCT03202381] | Phase 4 | 35 participants (Anticipated) | Interventional | 2017-06-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for flutamide and Low Bone Density
| Article | Year |
|---|---|
Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density; Bone Diseases, Metabolic; | 2010 |
Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormon | 2012 |
5 other studies available for flutamide and Low Bone Density
| Article | Year |
|---|---|
Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands.
Topics: Androgen Antagonists; Animals; Animals, Genetically Modified; Anti-Inflammatory Agents, Non-Steroida | 2004 |
Effect of androgen suppression on bone mineral density in patients with prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density; Bone D | 2014 |
Prostate cancer in elderly Croatian men: 5-HT genetic polymorphisms and the influence of androgen deprivation therapy on osteopenia--a pilot study.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Bone Density; Bone Diseases, Metabolic; Finasteride; | 2012 |
Flutamide-mediated androgen blockade evokes osteopenia in the female rat.
Topics: Androgens; Animals; Body Weight; Bone Density; Bone Diseases, Metabolic; Buserelin; Female; Flutamid | 1993 |
Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.
Topics: Absorptiometry, Photon; Adipose Tissue; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplasti | 2002 |